Reply: Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1677-1678

  Alvarez, R ^a   Musteanu, M ^b   Garcia Garcia, E ^b   Lopez Casas, P P ^b   Megias, D ^b   Guerra, C ^b   Munoz M ^b   Quijano, Y ^a   Cubillo, A ^a   Rodriguez Pascual, J ^a   Plaza, C ^a   De Vicente, E ^a   Prados, S ^a   Tabernero, S ^a   Barbacid, M ^b   Lopez Rios, F ^a   Hidalgo, M ^a,b  

^a Gynecolog ical and Genitourinary Tumors Programme Centro Integra Oncologico Clara Campal CIOCC   (Spain)

^b Centro Nacional de Investigations Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ANIMAL; FEMALE; FIBROBLAST; HUMAN; MALE; PANCREATIC NEOPLASMS; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FIBROBLASTS; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 84908885452     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.129     Document Type: Letter

References (6)

1. Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Munoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M (2013) Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 109: 926-933.
2. Boeck S, Haas M, Ormanns S, Kruger S, Siveke JT, Heinemann V (2014) Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult. Br J Cancer; e-pub ahead of print 18 March 2014; doi:10.1038/bjc.2014.60.
3. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2: 260-269.
4. Ramórez N, Viúdez A, Hernández-Garc?á I, Guerrero D, Gómez-Dorronsoro M, Herrera FJ, Vila J, Beloki L, Ciaúrriz M, Mansilla C, Vera R (2014) Stellate cells, a point of light in the dark night of pancreatic cancer. Br J Cancer; e-pub ahead of print 18 March 2014; doi:10.1038/bjc.2014.59.
5. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18): 1691-1703.
6. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29: 4548-4554.